News ReleaseView printer-friendly version << Back
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
“We are pleased with the continued success of EXPAREL in the fourth
quarter, growth over the previous quarter and growth for the year, which
we expect to provide the basis of a strong 2015,” said
Fourth Quarter 2014: Pacira expects
$59.0 millionin net revenue for EXPAREL in the fourth quarter of 2014, which represents an increase of:
93 percent over
$30.5 millionin the fourth quarter of 2013.
18 percent sequentially over
$50.2 millionin the third quarter of 2014.
- 93 percent over
Full-Year 2014: Pacira also expects
$188.5 millionin net revenue for EXPAREL in 2014, a 147 percent increase over $76.2 millionin 2013.
Fourth Quarter 2014: Pacira expects total revenues of
$61.8 millionin the fourth quarter of 2014, which represents an increase of:
84 percent over
$33.6 millionin the fourth quarter of 2013.
19 percent sequentially over
$52.0 millionin the third quarter of 2014.
- 84 percent over
Full-Year 2014: Pacira also expects total revenues of
$197.7 millionin 2014, a 131 percent increase over $85.6 millionin 2013.
Pacira will provide final financial results and additional information on its financial performance in conjunction with the fourth quarter and year-end 2014 earnings press release and conference call anticipated in late February.
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with a 45% decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about our expected revenues,
and other statements containing the words “believes,” “anticipates,”
“plans,” “estimates,” “expects,” and similar expressions, constitute
forward-looking statements within the meaning of
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574
Pure Communications, Inc.
Susan Heins, 864-286-9597